| Code | CSB-RA004930MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to nebratamig2, targeting CD3D (CD3 delta), an essential component of the T-cell receptor (TCR) complex. CD3D forms a heterodimer with CD3 epsilon and associates with the TCR to transduce signals critical for T-cell activation, differentiation, and immune responses. As part of the CD3 complex, CD3D plays a fundamental role in adaptive immunity and is involved in various immunological disorders, autoimmune diseases, and cancer immunotherapy strategies. Dysregulation of CD3D expression or function has been implicated in immunodeficiency syndromes and aberrant T-cell responses.
Nebratamig2 represents a bispecific antibody platform designed to engage T-cells through CD3 binding while simultaneously targeting tumor-associated antigens. This biosimilar antibody provides researchers with a valuable tool for investigating T-cell biology, studying CD3-mediated signaling pathways, evaluating immune checkpoint mechanisms, and exploring novel immunotherapeutic approaches in oncology and autoimmune disease models. It supports studies examining T-cell receptor complex assembly, T-cell activation dynamics, and immune cell interactions in various experimental contexts.
There are currently no reviews for this product.